Connect your AI

Evommune EVMN Q3 2025 earnings

Reported December 11, 2025 · Before market open

Revenue$10.0MBeat by $6.7M Diluted EPS-$8.07Miss by $1.99

Revenue estimate$3.3M

EPS estimate-$6.08

Next report

Aug 6, 2026 (in a month)

Revenue estimate$1.3M

EPS estimate-$0.68

Financials

Q3 2025

Income statement

Revenue$1.7M+21.4%

Gross profit$978.4K+28.1%

Operating income-$78.3K+64.2%

Net income$259.0K+190%

EPS (diluted)$0.04+200%

Balance sheet

Cash & equivalents$997.6K+299%

Total debt$2.0M—

Total equity$604.7K+336%

Total assets$8.2M—

Valuation & ratios

Profitability

Gross margin55.9%—

Operating margin-5.9%—

Returns & leverage

Debt / equity3.4×—

Current ratio0.7×—

Versus estimates

Revenue

Q3 2025$10.0MBeat by $6.7M

Diluted EPS

Q1 2026-$0.64Beat by $0.19 Q4 2025-$1.43Miss by $0.61

Q3 2025-$8.07Miss by $1.99

Ask the moment Evommune reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Harbor at dusk

Questions, answered.

When did Evommune report Q3 2025 earnings?: Evommune (EVMN) reported Q3 2025 earnings on December 11, 2025 before market open.
What were Evommune 's Q3 2025 revenue and EPS?: Evommune reported revenue of $10.0M and diluted EPS of $-8.07 for Q3 2025.
Did Evommune beat estimates in Q3 2025?: Revenue beat the consensus estimate of $3.3M by $6.7M. EPS missed the consensus estimate of $-6.08 by $1.99.
Where can I find Evommune 's Q3 2025 SEC filings?: You can read the 10-Q periodic report (0001213900-25-121689) directly on SEC EDGAR. The filing index links above go to sec.gov.